Informed consent was obtained at baseline endoscopy, which was performed using diazepam for sedation. An ulcer was defined as a localised defect in gastric or duodenal mucosa of at least 5 mm in diameter and with perceptible depth, whereas smaller lesions were considered as erosions. Ulcer dimensions were measured using standard Olympus biopsy forceps, with the fully open spoon being equivalent to 5 mm.
Study design
Hpylori was determined by a biopsy urease test and histological assessment. For this purpose, apart from specimens from gastric ulcer edges, three biopsy specimens were taken from the antrum and two from the corpus. One antral biopsy specimen was used for the rapid urease test (CP test, Brocades, Milan, Italy), whereas the remaining formalin fixed specimens were used for histological assessment. The specimens were embedded in paraffin wax and stained with haematoxylin and eosin and modified Giemsa methods. Gastric histopathology was classified according to a personal modification of the Sydney system as previously described.8 A patient was considered H pylori positive when H pylori was found at histological examination and rapid urease test was positive.
Patients with active gastric or duodenal ulcer at initial endoscopy were asked to participate in a prospective trial to evaluate the effect of H pylon on ulcer healing and recurrence.
The presence of concurrent gastric or duodenal erosions did not constitute a criterion for exclusion from the trial. According to their H pylori status they were assigned to the following ulcer healing treatments: H pylori positive patients received omeprazole 20 mg twice daily for four weeks and amoxycillin 1 g twice daily during the first two weeks or omeprazole 20 mg twice daily alone for four weeks according to a randomised single blind scheme. H pylori negative patients were all treated with omeprazole 20 mg twice daily for four weeks. Patients also continued to take NSAIDs at the same dose given prior to the study during both the ulcer healing and ulcer recurrence phases of the study. Patient compliance to antiulcer treatment was determined by counting all the unused tablets reported by the patients at fortnightly clinical assessments; during these visits side effects were specifically asked for and recorded.
After four weeks patients were endoscoped again to assess ulcer healing; if the ulcer was still active they received an open therapy with omeprazole 20 mg twice daily for a further four weeks.
Patients were considered to have been cured of H pylori if both rapid urease test and histological examination in the antrum and corpus were negative. In patients whose ulcer had healed at four weeks, H pylori eradication was assessed after one month from stopping treatment; in patients whose ulcer healed at eight weeks, because of the possibility of a false negative result at this time while receiving omeprazole, H pylon status was taken on the basis of the result of biopsies done at three months during the follow up. Similarly, in patients with unhealed ulcer after eight weeks, H pylori status was re-evaluated one to three months afterwards while they were receiving alternative therapy (sucralfate, misoprostol) after stopping NSAIDs.
Patients with healed ulcers at eight weeks, irrespective of their H pylon status, were asked to participate in the second part of the study. During this phase patients continued to take NSAIDs at the same dose given during the ulcer healing phase for a further six months but stopped any antiulcer therapy. Endoscopy was repeated at 12 and 24 weeks of follow up or before in the case of a recurrence of ulcer symptoms, with the endoscopist unaware of the Hpyloni status of the patients. Patients who took at least 85% of the antiulcer treatment, who missed no more than two consecutive days of NSAID therapy, and who had both the second and third endoscopic examination were considered evaluable for the first end point of the study.
Any patient who took at least 70% of NSAID therapy and did not miss more than three consecutive days of treatment during the longterm phase was considered evaluable for the second end point of the study. Eleven patients with gastric ulcer and five with duodenal ulcer were still unhealed after eight weeks of treatment. However, in both groups the maximum ulcer diameter significantly reduced during treatment, thus suggesting a slow response rather than resistance to treatment. Indeed, for these gastric ulcers the mean diameter fell from 7 (before therapy) to 3-6 mm (at eight weeks) with a 49°/O reduction and, similarly, for the duodenal ulcers, it reduced from 6-2 to 3.5 mm corresponding to a reduction of 42%.
Ulcer recurrence phase A total of 62 patients with healed peptic ulcer after eight weeks of acute antiulcer treatment entered this phase of the study. They were subdivided into three different groups according to their baseline H pylori status: 19 patients were H pylori negative (group A), 29 patients had persistent H pylori infection after short-term therapy (group B) whereas 14 patients had been cured of H pylori after the short-term phase (group C). Fifty nine patients completed the study correctly and were therefore evaluable: 18 in group A, 28 in group B, and 13 in group C. Three patients defaulted: one in group A failed to attend the three month endoscopic control, another in group B refused to have another endoscopy at six months, and one in group C did not adhere strictly to NSAID treatment. Table III shows the cumulative recurrence rate at six months for the three different groups.
There were no significant differences between groups although a numerical trend towards a lower rate of recurrence was evident in H pylon negative and patients cured of H pylori compared with those with persistent H pylori infection.
Discussion
Despite the fact that it is now well accepted that NSAIDs and Hpylori have distinct pathogenic roles in peptic ulcer disease, the relation between these two factors remains unclear.' Current evidence seems to show that the presence of H pylon infection does not constitute a significant additional risk factor for NSAID gastropathy,2 3 67 9-11 but it is suspected that NSAID use exacerbates H pylon ulcers and therefore the existence of a small group of patients whose ulcers results from an interaction between H pylon and NSAIDs could be hypothesised. This is indirectly supported by a study that showed that peptic ulcers in longterm NSAID users are more likely to develop in patients with H pylori positive duodenal erosions.4
Whether or not Hpyloni and NSAIDs have a synergistic relation in NSAID associated ulcers can be best considered by a prospective study evaluating the role of eradicating Hpyloni in the healing and recurrence of these ulcers such as reported here. In a large population of arthritic patients taking longterm NSAID treatment we found a prevalence of longterm gastric or duodenal ulceration of 36% (100 of 278). This is consistent with previous studies performed by us and by other authors reporting that NSAID associated peptic damage occurs in approximately 30% of NSAID users.12 13 Fifty eight per cent of the patients studied were H pylon positive, which is what can be expected in a Western control population of similar age and in line with the data previously reported by others in arthritic patients.3 7 14 Most (70%) NSAID associated ulcers were associated with H pylon infection and antral gastritis; this concurs well with that seen by Shallcross et al6 who showed that in ulcer patients taking NSAIDs, approximately three quarters are H pylon positive. However, the fact that as many as 30% of these ulcers occurred in uninfected patients strengthens the theory that these drugs exert an ulcerogenic effect that does not necessarily require the presence of Hpyloni or gastritis. '5 One of the most important results of the ulcer healing phase of our study was that the cumulative healing at eight weeks, especially for gastric ulcers, was fairly poor (approximately 80%), considering that these patients were all receiving 40 mg omeprazole per day. This finding differs from that seen by Walan et al16 in a multicentre trial comparing ranitidine with omeprazole in gastric ulcers, where omeprazole seemed more effective. However, in the second study NSAIDs were used simply on demand and not daily as for our patients. Our results, therefore, suggest that irrespective of the cause, the regular use of NSAIDs delays ulcer healing even with omeprazole treatment and not only under treatment with less potent agents (ranitidine) as already reported. '7 18 Unlike non-NSAID associated peptic ulcers where healing is increased by H pylori eradication,19 we found that H pylori infection has not a clear influence on healing of NSAID associated peptic ulcers. Indeed, healing rates of both duodenal and gastric ulcers did not significantly differ between patients with persistent H pylori infection and those in whom the organism had been eradicated. On the other hand, it should be emphasised that the H pylori cure rate obtained with omeprazole/ amoxycillin in these patients (that is 56%) is comparable with that we and others have reported in non-NSAID related peptic ulcers using the same combination. '9-22 In addition, we showed that H pylon eradication did not significantly reduce the frequency of recurrence in patients who continued to receive longterm NSAID treatment but stopped antiulcer medications. Unfortunately, the comparatively small number of ulcers (mainly duodenal ulcers) included in the longterm phase of our study does not completely exclude the possibility that H pylori infected patients taking NSAIDs would not have an increased risk of developing ulcer recurrence compared with H pylon negative patients; this is particularly true if we consider the existence of a numerical trend but not statistically significant in favour of a higher recurrence rate in infected compared with uninfected patients or those cured from the infection and the fact that we did not compare each one of the two common causes of ulcer with both together. The 
